LIVE BUSINESS: AstraZeneca forecasts sales of $80 billion; Credit card market research; The ‘big bill’ of the kingfisher

There is little evidence that large increases in fees from Visa and Mastercard to retailers using their cards have also led to a major improvement in service, Britain’s Payment Systems Regulator said, flagging concerns that competition It was not working.

Visa and Mastercard have long dominated the payment card market, prompting calls from UK lawmakers for closer scrutiny by the PSR, which launched an investigation.

‘The PSR found that over the past five years, and after taking into account changes in volume, Mastercard and Visa have increased their processing schemes and fees by more than 30 per cent in real terms. “There is little evidence that service quality has improved at the same rate,” the PSR said in a statement.

A major Anglo American shareholder has backed the miner’s plan to split as the deadline for a new bid from BHP approaches.

Last week, Anglo unveiled a restructuring as it fights a takeover by its Australian rival.

Legal and General Investment Management (LGIM), which holds just under 2 per cent of the shares, said yesterday it approved the proposals, which include a plan to sell the company’s diamond unit, De Beers.

AstraZeneca expects to generate $80 billion in total revenue by 2030, driven by the planned launch of 20 new drugs and by growing its existing oncology, biopharmaceuticals and rare diseases portfolio, the drugmaker told investors on Tuesday.

The drugmaker said in a statement that it would continue to invest in new technologies and platforms that will “shape the future of medicine” beyond 2030.

Pascal Soriot, CEO of AstraZeneca, said: “Today AstraZeneca announces a new era of growth.

‘In 2023 we meet the ambitious revenue target of $45 billion set a decade ago. With the exciting growth of our innovative portfolio, which has the potential to transform millions of lives, we are now targeting $80 billion by 2030.’